Mobile

Open-label, randomised trial to evaluate the efficacy and safety of MOR00208 with bendamustine versus rituximab with bendamustine in adult patients with a cancer of B cells, a type of white blood cell...

Mise à jour : Il y a 4 ans
Référence : EUCTR2014-004689-11

Open-label, randomised trial to evaluate the efficacy and safety of MOR00208 with bendamustine versus rituximab with bendamustine in adult patients with a cancer of B cells, a type of white blood cell responsible for producing antibodies, which has returned after a period of improvement or that has proved resistant, or does not respond to, treatment

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To determine the efficacy of a combination of MOR00208 with BEN versus a combination of RTX with BEN in terms of progression-free survival (PFS) in adult patients with R-R DLBCL.

Critère d'inclusion

  • Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R-R DLBCL)

Liens